Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.
Mukherjee
Kaushik
K
Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Chakravarthy
A Bapsi
AB
Goff
Laura W
LW
El-Rifai
Wael
W
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D064127:Aurora Kinases; D001471:Barrett Esophagus / Q000473:pathology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D016629:Esophagectomy; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000494:pharmacology; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases